Is Dupixent Linked to Lymphoma?

Where The Dupixent–Lymphoma Question Comes From

The Dupixent–lymphoma question grew out of post-marketing reports, not the original approval trials, where no lymphoma or cutaneous lymphoma cases were identified during the phase 2 and 3 studies that supported dupilumab’s 2017 approval for atopic dermatitis.

Early concern came from case reports and small series describing patients treated with dupilumab for presumed eczema who were later diagnosed with cutaneous T-cell lymphoma, or CTCL, after persistent or changing skin disease.

That pattern drew attention because CTCL can closely resemble severe eczema in its early stages, making it difficult to tell whether Dupixent was tied to new cancer, disease progression, or a delayed diagnosis of lymphoma already present before treatment began.

As more reports accumulated, larger observational studies began looking for measurable signals in real-world populations.

A real-world JID analysis and later JAAD and Dermatologic Therapy publications reported that some patients treated with dupilumab appeared to face a higher risk of CTCL diagnosis than comparison groups, while other authors argued that this may reflect “unmasking” of previously misdiagnosed lymphoma rather than a direct causal effect.

Research then expanded beyond dermatology, including an asthma cohort that found more new-onset lymphoma, especially T-cell and natural killer cell subtypes, among dupilumab users than among patients on standard inhaled corticosteroids, even though dupilumab was also associated with lower all-cause mortality.

In parallel, FDA adverse-event surveillance identified CTCL as a potential safety signal under review, which moved the issue from scattered case reports into a formal regulatory setting.

Today, the alleged link remains unsettled, but the timeline is clear: isolated reports came first, broader studies followed, the FDA opened review, and lawsuits now argue that patients treated with Dupixent should have been warned earlier about the possible lymphoma linked signal and the need to investigate suspicious skin changes more aggressively.

What Dupixent Is Designed To Do

Dupixent is the brand name for dupilumab, a fully human IgG4 monoclonal antibody that binds to the interleukin-4 receptor alpha (IL-4Rα) subunit.

By blocking that receptor, dupilumab treatment inhibits signaling from IL-4 and IL-13, two cytokines that drive type 2 inflammation in the skin, airways, sinuses, and other tissues.

Dupixent is not a steroid or a traditional immunosuppressant.

It is designed to reduce a specific inflammatory pathway that contributes to itching, rash, airway inflammation, nasal polyp disease, and related symptoms in many patients with atopic dermatitis and other allergic or eosinophilic conditions.

In practice, Dupixent is often used when patients with atopic dermatitis, asthma, or similar diseases remain symptomatic despite standard treatment.

That includes people with severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, as well as many patients who are starting Dupixent after cycles of flares, steroid use, or inadequate response to other maintenance options.

The drug is given by subcutaneous injection on a schedule that varies by age, weight, and diagnosis.

Dupixent is currently FDA-approved for:

• Atopic dermatitis in adult and pediatric patients aged 6 months and older with moderate-to-severe disease not adequately controlled with topical prescription therapies, or when those therapies are not advisable.
• Asthma as add-on maintenance treatment for adults and children aged 6 years and older with moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma.
• Chronic rhinosinusitis with nasal polyps in adults and adolescents aged 12 years and older.
• Eosinophilic esophagitis in adults and children aged 1 year and older who meet the weight requirement in the label.
• Prurigo nodularis in adults.
• Chronic obstructive pulmonary disease (COPD) in adults with an eosinophilic phenotype.
• Chronic spontaneous urticaria in patients aged 12 years and older who remain symptomatic despite H1 antihistamine treatment.
• Bullous pemphigoid in adults.
• Allergic fungal rhinosinusitis in adults and children aged 6 years and older with a history of sino-nasal surgery.

Dupilumab treatment now spans dermatology, pulmonology, allergy, gastroenterology, and ENT care, with patients using the drug for skin disease, asthma, sinus disease, eosinophilic esophagitis, and other chronic inflammatory conditions.

How is Dupixent Potentially Linked to Lymphoma?

Cutaneous T-cell lymphoma, or CTCL, is a rare non-Hodgkin lymphoma that begins in abnormal T cells and usually shows up first in the skin, most often as persistent patches, plaques, or other rash-like lesions rather than as an obvious internal cancer.

Early CTCL can look very similar to severe eczema or dermatitis, which is one reason the Dupixent debate has focused so heavily on whether some patients already had undiagnosed lymphoma before treatment started.

Major medical sources note that CTCL often develops slowly, but some cases progress from flat, itchy, scaly patches to thicker plaques, tumors, blood involvement, swollen lymph nodes, or spread beyond the skin.

That clinical overlap is what drives the three main theories linking the drug to an increased risk of lymphoma.

One theory is that Dupixent increased lymphoma risk by helping some patients develop CTCL or another T-cell lymphoma after treatment began.

Another is that Dupixent did not create a new cancer at all, but instead changed the inflammatory picture enough to reveal CTCL that had been mistaken for severe eczema.

A third theory focuses on delayed diagnosis, arguing that when suspicious skin disease was treated as refractory dermatitis for too long, the cancer had more time to progress before doctors recognized what it was.

At this stage, the evidence supports careful scrutiny and further research, but not a settled conclusion that Dupixent directly causes lymphoma in every patient who later receives that diagnosis.

Did Dupixent Cause New Lymphoma?

The strongest evidence used to argue that Dupixent may have caused new lymphoma comes from observational studies and post-marketing reports, not from the original clinical trials that led to approval.

In those early trials, no lymphoma or cutaneous lymphoma cases were reported, which means the concern surfaced later as doctors began seeing lymphoma diagnoses in real-world patients after dupilumab exposure.

Some of the most cited studies have found a measurable association between dupilumab use and later CTCL diagnosis, while others argue the signal may reflect misdiagnosed eczema rather than cancer newly created by the drug.

A 2025 population-based asthma cohort also found more new-onset lymphoma in dupilumab users than in matched patients on standard inhaled therapy, which is one reason the “new lymphoma” theory remains part of the scientific debate.

At the same time, none of these studies proves direct causation, and each leaves open the possibility that Dupixent revealed or accelerated disease that was already present at a microscopic or misdiagnosed stage.

Studies and reports most often cited on the “new lymphoma” question include:

• European Respiratory Journal asthma cohort (2025): This population based cohort study found that asthma patients who initiated dupilumab had a higher incidence of new-onset lymphoma than matched patients on inhaled corticosteroid/LABA therapy, with the signal strongest for T-cell and natural killer cell lymphomas. The same study also found lower all-cause mortality in the dupilumab group, which makes the safety picture more complicated rather than one-directional.
• Dermatologic Therapy / Jefferson TriNetX study (2024): In a matched atopic dermatitis retrospective cohort study, patients treated with dupilumab had a reported 4.59-fold relative risk of later CTCL diagnosis compared with non-users. Most CTCL diagnoses after dupilumab occurred within the first year, and a substantial share involved older adults, which is why this study is repeatedly cited in Dupixent litigation.
• JID real-world pharmacovigilance analysis (2024/2025): This work drew attention to biopsy-proven CTCL occurring after dupilumab use in real-world settings and helped move the issue beyond scattered anecdotes into a more structured safety discussion. It supports the existence of a signal, but it does not resolve whether dupilumab caused a truly new cancer or exposed one that was already present.
• JAAD case series of 18 patients (2024): This series documented patients diagnosed with CTCL after dupilumab treatment for presumed atopic dermatitis, with a median time to diagnosis of about 10 months. The short interval is important because it can be read two different ways: either as evidence of rapid emergence after drug exposure or as evidence that CTCL was present but not correctly identified before treatment.
• JACI integrative epidemiology and immunotranscriptomics paper (2024): This study explored biologic mechanisms that might connect IL-4/IL-13 blockade with CTCL risk and progression. It offers a plausible mechanistic framework for why dupilumab could contribute to lymphoma biology, but it remains hypothesis-generating rather than definitive proof.

Several authors point out that observational studies can be affected by background lymphoma risk in severe inflammatory disease, case selection, and the possibility that CTCL was already present before dupilumab exposure.

The short interval between treatment and diagnosis in many reported cases cuts both ways: some readers see rapid emergence after drug exposure, while others see previously missed disease becoming easier to detect.

Did Dupixent Unmask Cancer That Was Already There?

The strongest alternative to the “new lymphoma” theory is that some patients already had early cutaneous T-cell lymphoma before Dupixent was prescribed, but the disease was mistaken for severe eczema or another inflammatory skin disorder. CTCL is well known to mimic dermatitis in its early stages, and that overlap matters most in atopic dermatitis receiving dupilumab, where the starting diagnosis is often a chronic pruritic rash rather than a suspected malignancy.

A growing set of dermatology publications describes dupilumab associated lymphoma as being more complex and not a simple drug-causes-cancer narrative, because the same pattern can reflect misdiagnosis, disease evolution, immune effects, or some combination of those explanations.

The unmasking theory gains force from the fact that CTCL reports are concentrated in dermatology patients, while research in asthma receiving dupilumab raises a different set of questions because those patients are less likely to have preexisting CTCL hidden inside an eczema diagnosis.

Publications most often cited in support of the unmasking theory include:

• “Decoupling the association of dupilumab with cutaneous T-cell lymphoma” (JAAD, 2024): This letter argues that the association seen in TriNetX data may be explained by CTCL patients initially misdiagnosed with atopic dermatitis, then “unmasked” when they failed to improve on dupilumab and underwent more definitive evaluation.
• “Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab” (JAAD, 2023): This report emphasizes that mycosis fungoides can masquerade as eczema and presents dupilumab as a clinical moment when previously smoldering CTCL may become easier to recognize.
• “Did dupilumab unmask smoldering mycosis fungoides?” (JAAD Case Reports, 2023): This case-based discussion explicitly frames dupilumab as a possible trigger for recognition of previously unrecognized mycosis fungoides rather than proof of a newly created cancer.
• “Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial and Complex Association” (JID, 2024): This commentary states that the relationship is not one-dimensional and suggests the observed signal may arise from several mechanisms, including baseline disease confusion, selective recognition, and biologic effects.
• American Journal of Clinical Dermatology review, “Dupilumab and Cutaneous T-Cell Lymphoma: A Call for Vigilance, Not Alarm” (2025): This review treats unmasking as a serious and plausible explanation for many dermatology cases while also noting that it may not explain every lymphoma signal seen outside eczema populations.

Did Dupixent Contribute To Delayed Diagnosis?

In some patients, the central problem may not be that Dupixent created a new cancer, but that cutaneous T-cell lymphoma continued to be treated as severe eczema after warning signs were already present.

A 2024 JAAD retrospective study on delays in CTCL diagnosis explains that these cancers often mimic benign inflammatory skin disease, which can lead to years of ineffective treatment before the correct diagnosis is made.What Larger Studies Have Found

Another JAAD update on primary cutaneous lymphomas states that persistent patches or plaques that do not respond to usual therapy, expanding tumors, or erythroderma should keep lymphoma in the differential diagnosis and warrant a low threshold for biopsy.

Several reports describe patients whose presumed atopic dermatitis did not improve, changed pattern, or worsened before repeat biopsies finally identified CTCL.

Publications that support the delayed-diagnosis theory include:

• “Delays in diagnosis in cutaneous T-cell lymphoma: A retrospective study” (JAAD, 2024): This study focuses directly on diagnostic lag in CTCL and explains that the disease often resembles benign inflammatory dermatoses, leading to delayed recognition and ineffective or even harmful treatment.
• “Bridging the specialty gap: Update on primary cutaneous lymphomas” (JAAD, 2023): This review states that persistent plaques, tumors, erythroderma, or disease unresponsive to usual therapies should keep primary cutaneous lymphoma on the differential diagnosis and justify prompt biopsy.
• “Progression of cutaneous T-cell lymphoma after dupilumab: Case review” (JAAD, 2020): This report describes patients initially treated as atopic dermatitis who were later diagnosed with CTCL, along with progression in some patients during treatment.
• “Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis” (JAAD, 2025): This publication discusses several explanations for the pattern seen after biologic exposure, including delayed recognition of CTCL in patients first labeled as having advanced atopic dermatitis.

FDA Review And Safety Monitoring

The FDA has not concluded that Dupixent causes lymphoma, and it has not added a lymphoma or cancer warning to the current U.S. prescribing information.

The agency’s current label for Dupixent includes warnings about hypersensitivity, conjunctivitis and keratitis, eosinophilic conditions, acute worsening of asthma or COPD, steroid tapering, psoriasis, psoriatic arthritis, parasitic infection, and vaccination, but it does not list cutaneous T-cell lymphoma as an established adverse reaction or warning.

What the FDA has done is identify CTCL as a potential risk signal through its post-marketing surveillance system.

Under the FDA’s FAERS process, a drug’s appearance on a quarterly “potential signals” report means the agency has detected a signal worth evaluating, not that it has confirmed a causal relationship or told patients to stop treatment.

The FDA’s own explanation of FAERS says these quarterly postings reflect signals under evaluation and may lead to more data gathering, labeling changes, REMS action, market withdrawal, or no action at all, depending on what the review ultimately shows.

For Dupixent specifically, the relevant FDA action first appears in the agency’s October–December 2024 FAERS quarterly report.

In that report, the FDA lists “Dupixent (dupilumab) injection – Cutaneous T-cell lymphoma” and states that the agency is “evaluating the need for regulatory action.”

As of the FDA’s later January–March 2025 quarterly report, Dupixent does not appear again as a new signal, which is consistent with the FDA’s rule that a signal is posted in the quarter in which it is first identified and then followed through later regulatory action or continued evaluation rather than repeated every quarter as a new posting.

The FDA’s public materials do not show a formal Drug Safety Communication dedicated to Dupixent and lymphoma, and the current label still contains no lymphoma warning.

That means the agency’s public posture remains cautious: CTCL has been recognized as a signal serious enough to review, but the FDA has not publicly said that dupilumab causes lymphoma, has not instructed prescribers to stop using the drug, and has not yet converted the signal into a label-based cancer warning.

FDA-related milestones include:

• 2017: Dupixent receives initial FDA approval for moderate-to-severe atopic dermatitis. The approval record and subsequent labeling history matter because lymphoma was not identified as a warning at approval, which means the issue emerged later through post-marketing monitoring rather than pre-approval trials.
• Post-approval years: FDA continues routine FAERS surveillance for Dupixent, like it does for other marketed drugs and biologics. FDA explains that FAERS is part of its ongoing post-marketing safety program and that staff in CDER and CBER regularly screen adverse-event data for new safety information or serious-risk signals.
• October–December 2024: CTCL is first posted as a FAERS signal for Dupixent. The FDA’s quarterly report lists Dupixent (dupilumab) injection – Cutaneous T-cell lymphoma and states that FDA is evaluating the need for regulatory action. The report’s “as of” date is March 6, 2025.
• March 2025: FDA’s public record reflects active review rather than final action. The quarterly FAERS posting and FDA’s general FAERS explanation make clear that listing a product does not mean FDA has confirmed the drug has the listed risk; it means the agency is evaluating the signal.
• January–March 2025 quarterly report: no repeat “new signal” posting for Dupixent. FDA’s FAERS page explains why: signals are posted in the quarter they are first identified, and additional developments are handled through later communications or actions rather than repeated as new listings every quarter.
• 2025 label updates: Dupixent’s FDA-approved prescribing information changes in other areas, not lymphoma. The 2025 label shows revisions for other warnings and precautions, plus new indications, but still no CTCL-specific or general cancer warning.
• Current status as of early 2026: signal under review, no formal cancer warning. The latest accessible FDA-approved label still omits lymphoma from the Warnings and Precautions section, which means the agency has not yet translated the FAERS signal into a formal boxed warning or lymphoma-specific label change.

What Patients Should Pay Attention To

Patients on dupilumab therapy should pay attention to skin disease that stops behaving like ordinary eczema, especially when patches become thicker, more widespread, more painful, or less responsive to treatment over time.

Persistent plaques, nodules, tumors, or rash patterns that keep changing despite medication can justify a closer workup rather than another assumption that the condition is still atopic dermatitis.

Enlarged lymph nodes, fevers, night sweats, or unexplained weight loss can also raise concern that something more than an inflammatory skin condition is going on.

CTCL and related lymphomas are uncommon, but one of the recurring issues in Dupixent-related reports is that suspicious symptoms were sometimes treated as refractory eczema before the diagnosis changed.

Medical records, photographs, biopsy reports, and notes showing how the skin condition evolved can all become important when doctors are reassessing the diagnosis or when a lawyer later reviews the case.

Signs and developments that deserve closer attention include:

• Red, scaly patches or plaques that do not improve with standard eczema treatment
• Skin lesions that become thicker, darker, raised, or tumor-like
• Itching that becomes more intense or starts to feel different from prior flares
• Rash patterns that spread to new body areas or behave differently than before
• Enlarged lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, fevers, or night sweats
• Repeat flares after initially modest improvement on Dupixent
• Biopsy results that are inconclusive, nonspecific, or followed by continued worsening symptoms
• Adult-onset “eczema” that appears severe, persistent, or unusual in presentation

Do You Qualify for the Dupixent Lawsuit?

Eligibility for the Dupixent lawsuit usually starts with a documented diagnosis of cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma after use of the drug.

Current Dupixent cases are still in the early stages, with individual suits already filed and at least one wrongful death claim alleging a lymphoma-related death after treatment, while lawyers continue pushing for coordinated federal litigation.

Most claims allege that Sanofi and Regeneron failed to warn patients and prescribing doctors about a possible link between Dupixent and CTCL, or about the risk that lymphoma symptoms could be mistaken for severe eczema.

Lawyers look closely at why Dupixent was prescribed, when treatment started, how long it continued, and when suspicious skin changes, biopsy findings, or systemic symptoms first appeared.

People who may qualify often include those who used Dupixent for eczema, asthma, or another approved condition and were later diagnosed with CTCL or another lymphoma supported by pathology and treatment records.

If a loved one died after developing lymphoma during or after Dupixent use, the family may also have grounds to explore a wrongful death claim, depending on the timeline and available medical evidence.

The only way to know whether you qualify is to compare your diagnosis, treatment history, and symptom progression against the medical and legal patterns now emerging in these Dupixent cases.

TorHoerman Law: Reviewing Dupixent Lymphoma Claims

TorHoerman Law is reviewing Dupixent lymphoma claims involving cutaneous T-cell lymphoma, related T-cell cancers, delayed diagnosis, and allegations that patients were not adequately warned about the possibility of serious disease behind persistent “eczema” symptoms.

These cases turn on details in the medical record, including when Dupixent was prescribed, how the skin condition changed over time, when biopsies were performed, and when lymphoma was finally diagnosed.

A careful review of that timeline can help determine whether a Dupixent lawsuit may be appropriate.

If you or a loved one used Dupixent and later developed CTCL or another lymphoma, contact TorHoerman Law for a free case evaluation.

Our team can review your diagnosis, treatment history, and supporting records to assess whether your circumstances fit the claims now being investigated. Reach out today to discuss your legal options.